ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023
Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 4 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Factors affecting the impact of COVID-19 vaccination on post COVID-19 conditions among adults: A systematic literature review.Human vaccines & immunotherapeutics · 2025Pooled it
- A systematic review and meta-analysis of the impact of vaccination on prevention of long COVID.Nature communications · 2025Pooled it
- Evidence on the associations and safety of COVID-19 vaccination and post COVID-19 condition: an updated living systematic review.Epidemiology and infection · 2025Pooled it
- A systematic review of the evidence on the associations and safety of COVID-19 vaccination and post COVID-19 condition.Epidemiology and infection · 2023Pooled it
- Human brain matters: Navigating the neuropathology of COVID-19.Brain pathology (Zurich, Switzerland) · 2026Review
- Article
- Post-Exertional Malaise in Post-COVID-19 Syndrome: A Shift in the Frequency Across Pandemic Phases.Journal of clinical medicine · 2026Article
- Persistent Symptoms After SARS-CoV-2 Infection in a Referred Occupational Clinical Registry: Symptom Patterns and Associated Factors.Diseases (Basel, Switzerland) · 2026Article
- Prevalence of and risk factors for post-coronavirus disease 2019 symptoms after severe acute respiratory syndrome coronavirus 2 infection in healthcare workers: A multicenter cross-sectional study in China.The Journal of international medical research · 2026Article
- Effect of a Third COVID-19 Vaccine Dose on the Incidence of Long COVID Among Adults Who Completed a Primary Vaccine Series: a Target Trial Emulation in a Community-Based Cohort.medRxiv : the preprint server for health sciences · 2025Article
- Article
- Chronic health consequences of the COVID-19 pandemic on school workers: a cross-sectional post-pandemic analysis.BMJ open · 2025Article
- Adult Long Coronavirus Disease 2019: Definition, Prevalence Pathophysiology, and Clinical Manifestations.Infectious disease clinics of North America · 2025Review
- Tracking Survivors With Long COVID: Method, Implementation, and Results of an Observational Study.Research in nursing & health · 2025Observational
- Glial activation among individuals with neurological post-acute sequelae of coronavirus disease 2019: A positron emission tomography study of brain fog using [Brain, behavior, & immunity - health · 2025Article
- Identifying influencing factors and constructing a prediction model for long COVID-19 in hemodialysis patients.International urology and nephrology · 2025Article
- Real-world effectiveness and causal mediation study of BNT162b2 on long COVID risks in children and adolescents.EClinicalMedicine · 2025Article
- Long-term symptoms after SARS-CoV-2 infection in a cohort of people living with HIV.Infection · 2024Observational
- "A bit of a cough, tired, not very resilient - is that already Long-COVID?" perceptions and experiences of GPs with Long-COVID in year three of the pandemic. a qualitative interview study in Austria.BMC public health · 2024Article
- Risk of Reinfection and Incidence of Chronic Symptoms After SARS-CoV-2 Infections.Open forum infectious diseases · 2024Article
Corrections and comments
- Commented on by
Authors and funding
21 authors at 10 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDisentangling the effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and vaccination on the occurrence of post-acute sequelae of SARS-CoV-2 (PASC) is crucial to estimate and reduce the burden of PASC.
methodsWe performed a cross-sectional analysis (May/June 2022) within a prospective multicenter healthcare worker (HCW) cohort in north-eastern Switzerland. HCWs were stratified by viral variant and vaccination status at time of their first positive SARS-CoV-2 nasopharyngeal swab. HCWs without positive swab and with negative serology served as controls. The sum of 18 self-reported PASC symptoms was modeled with univariable and multivariable negative-binomial regression to analyze the association of mean symptom number with viral variant and vaccination status.
resultsAmong 2912 participants (median age: 44 years; 81.3% female), PASC symptoms were significantly more frequent after wild-type infection (estimated mean symptom number: 1.12; P < .001; median time since infection: 18.3 months), after Alpha/Delta infection (0.67 symptoms; P < .001; 6.5 months), and after Omicron BA.1 infections (0.52 symptoms; P = .005; 3.1 months) versus uninfected controls (0.39 symptoms). After Omicron BA.1 infection, the estimated mean symptom number was 0.36 for unvaccinated individuals versus 0.71 with 1-2 vaccinations (P = .028) and 0.49 with ≥3 prior vaccinations (P = .30). Adjusting for confounders, only wild-type (adjusted rate ratio [aRR]: 2.81; 95% confidence interval [CI]: 2.08-3.83) and Alpha/Delta infections (aRR: 1.93; 95% CI: 1.10-3.46) were significantly associated with the outcome.
conclusionsPrevious infection with pre-Omicron variants was the strongest risk factor for PASC symptoms among our HCWs. Vaccination before Omicron BA.1 infection was not associated with a clear protective effect against PASC symptoms in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.